Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity Júlia Coelho França QuintanilhaVanessa Marcilio de SousaPatricia Moriel Review Article 13 June 2017 Pages: 223 - 233
Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells Li XuYingya FuXiaoli Han Original Article 08 June 2017 Pages: 235 - 242
Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma Kaiming RenRan XuWenjun Shi Original Article 09 June 2017 Pages: 243 - 250
Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer Matvey M. TsyganovMaxim B. FreidinNikolai V. Litviakov Original Article 10 June 2017 Pages: 251 - 260
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies Howard A. Burris IIIC. D. KurkjianJ. R. Infante Original Article 10 June 2017 Pages: 261 - 273
JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin Mingning QiuLongzhi KeJianjun Liu Original Article 12 June 2017 Pages: 275 - 286
Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity Chengcheng LiuLaura J. JankeMary V. Relling Original Article 16 June 2017 Pages: 287 - 293
Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes Dale R. MilesSteven A. LacyLinh T. Nguyen Original Article 20 June 2017 Pages: 295 - 306
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo Makoto UenoChung Pin LiJunji Furuse Original Article Open access 20 June 2017 Pages: 307 - 315
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats Richard A. ForsgårdVannina G. MarrachelliPia Österlund Original Article Open access 23 June 2017 Pages: 317 - 332
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer Kotoe TakayoshiHitoshi KusabaEishi Baba Original Article 26 June 2017 Pages: 333 - 342
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring Ida NetterbergElisabet I. NielsenMats O. Karlsson Original Article Open access 27 June 2017 Pages: 343 - 353
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study) Tadahiro ShojiEriko TakatoriToru Sugiyama Original Article Open access 27 June 2017 Pages: 355 - 361
Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients Wan-Su ParkGab-jin ParkDong-Seok Yim Original Article 28 June 2017 Pages: 363 - 369
Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine? Valerie ReliasAntonia MaloneyMuhammad Wasif Saif Original Article 29 June 2017 Pages: 371 - 375
Eribulin shows high concentration and long retention in xenograft tumor tissues Michiko SugawaraKrista CondonW. George Lai Original Article Open access 29 June 2017 Pages: 377 - 384
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring Dhanusha SabanathanAlison ZhangHoward Gurney Original Article 30 June 2017 Pages: 385 - 393
Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1) Xiaofei YanJian ZhaoRui Zhang Original Article 30 June 2017 Pages: 395 - 403
Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience Alberto A. MendivilMark A. RettenmaierBram H. Goldstein Original Article 01 July 2017 Pages: 405 - 410
Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation Wen-Chen OuyangYi-Wen LiaoPei-Ling Hsieh Original Article 06 July 2017 Pages: 411 - 419
Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy M. K. BossM. W. DewhirstI. Spasojevic Original Article Open access 06 July 2017 Pages: 421 - 431
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients Jürgen BurhenneLu LiuGerlinde Egerer Short Communication 13 June 2017 Pages: 433 - 439